Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Aclaris Therapts (ACRS)

Aclaris Therapts (ACRS)
1.0900 x 1 1.2000 x 50
Post-market by (Cboe BZX)
1.1000 -0.0300 (-2.65%) 04/22/25 [NASDAQ]
1.0900 x 1 1.2000 x 50
Post-market 1.0916 -0.0084 (-0.76%) 17:04 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.0950
Day High
1.1850
Open 1.1700
Previous Close 1.1300 1.1300
Volume 2,244,248 2,244,248
Avg Vol 903,512 903,512
Stochastic %K 13.71% 13.71%
Weighted Alpha -64.64 -64.64
5-Day Change -0.0800 (-6.78%) -0.0800 (-6.78%)
52-Week Range 0.9515 - 5.1700 0.9515 - 5.1700
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 122,358
  • Shares Outstanding, K 108,281
  • Annual Sales, $ 18,720 K
  • Annual Income, $ -132,070 K
  • EBIT $ -55 M
  • EBITDA $ -54 M
  • 60-Month Beta 0.53
  • Price/Sales 6.59
  • Price/Cash Flow N/A
  • Price/Book 0.79

Options Overview Details

View History
  • Implied Volatility 143.35% ( -78.00%)
  • Historical Volatility 58.97%
  • IV Percentile 66%
  • IV Rank 16.37%
  • IV High 815.52% on 04/09/25
  • IV Low 11.77% on 09/17/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 101
  • Volume Avg (30-Day) 54
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 1,606
  • Open Int (30-Day) 1,955

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.17
  • Number of Estimates 4
  • High Estimate -0.10
  • Low Estimate -0.31
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +29.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0500 +4.76%
on 04/10/25
Period Open: 1.6000
1.7750 -38.03%
on 03/25/25
-0.5000 (-31.25%)
since 03/21/25
3-Month
1.0500 +4.76%
on 04/10/25
Period Open: 2.6000
2.6000 -57.69%
on 02/06/25
-1.5000 (-57.69%)
since 01/22/25
52-Week
0.9515 +15.61%
on 05/29/24
Period Open: 1.2200
5.1700 -78.72%
on 11/19/24
-0.1200 (-9.84%)
since 04/22/24

Most Recent Stories

More News
Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody

ACRS : 1.1000 (-2.65%)
Aclaris Therapeutics to Participate in Two March Healthcare Conferences

ACRS : 1.1000 (-2.65%)
Aclaris: Q4 Earnings Snapshot

Aclaris: Q4 Earnings Snapshot

ACRS : 1.1000 (-2.65%)
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

ACRS : 1.1000 (-2.65%)
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

ACRS : 1.1000 (-2.65%)
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

ACRS : 1.1000 (-2.65%)
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ACRS : 1.1000 (-2.65%)
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ACRS : 1.1000 (-2.65%)
Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

ACRS : 1.1000 (-2.65%)
Aclaris Therapeutics Stock Surges On Licensing Deal, $80 Million Private Placement: Retail Sentiment Jumps

Leerink upgraded Aclaris to ‘Outperform’ from ‘Market Perform’ with its price target raised to $7 from $2; Piper Sandler upgraded the company to ‘Overweight’ from ‘Neutral.’

VHT : 245.35 (+1.91%)
VXF : 162.43 (+2.71%)
VTI : 259.03 (+2.55%)
ACRS : 1.1000 (-2.65%)

Business Summary

Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription...

See More

Key Turning Points

3rd Resistance Point 1.2367
2nd Resistance Point 1.2033
1st Resistance Point 1.1667
Last Price 1.1000
1st Support Level 1.0967
2nd Support Level 1.0633
3rd Support Level 1.0267

See More

52-Week High 5.1700
Fibonacci 61.8% 3.5585
Fibonacci 50% 3.0608
Fibonacci 38.2% 2.5630
Last Price 1.1000
52-Week Low 0.9515

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro